Abstract
Autism is a complex neurodevelopmental disorder that forms part of a spectrum of related disorders referred to as Autism Spectrum Disorders (ASD). Like other complex neurodevelopmental disorders (e.g., schizophrenia), ASD is thought to be the final common pathway of multiple etiological (largely genetic) and neuropathological mechanisms. In the absence of a biological marker, ASD is defined behaviorally, its clinical presentation characterized by impairments in reciprocal social interaction and in communication with others, and by a preference for repetitive, stereotyped behaviors. Our understanding of autism has changed dramatically over the past decade. We now know that autism is not one disorder, but several closely related “disorders”, including Asperger syndrome, atypical autism, and disintegrative disorder. They may involve a range of behaviors at different ages and degrees of functioning, thus the term “autism spectrum disorder”. Along with these changes in classification, there has been a greater understanding of the causes of autism. Developmental delay, epilepsy, minor facial and bodily abnormalities, increased rate of obstetrical complications, an unequal sex ratio, and extremes of head size represent subtle, but still not clearly defined, signs that autism is a neuropsychiatric disorder. It appears that pharmacological interventions may have a limited role to play in the overall therapy of the autistic child. Medications may be most helpful in reducing hyperactivity, impulsivity, and aggressive and obsessive behaviors. For the development of everyday life skills, one-on-one behavioral therapy seems to be mandatory.
Keywords: DSM-IV, ASD phenotype, Antipsychotics, Lithium, Cyproheptadine
Current Drug Therapy
Title: Autism Spectrum Disorders: Etiology and Pharmacotherapy
Volume: 2 Issue: 2
Author(s): Mohammad-Reza Mohammadi and Shahin Akhondzadeh
Affiliation:
Keywords: DSM-IV, ASD phenotype, Antipsychotics, Lithium, Cyproheptadine
Abstract: Autism is a complex neurodevelopmental disorder that forms part of a spectrum of related disorders referred to as Autism Spectrum Disorders (ASD). Like other complex neurodevelopmental disorders (e.g., schizophrenia), ASD is thought to be the final common pathway of multiple etiological (largely genetic) and neuropathological mechanisms. In the absence of a biological marker, ASD is defined behaviorally, its clinical presentation characterized by impairments in reciprocal social interaction and in communication with others, and by a preference for repetitive, stereotyped behaviors. Our understanding of autism has changed dramatically over the past decade. We now know that autism is not one disorder, but several closely related “disorders”, including Asperger syndrome, atypical autism, and disintegrative disorder. They may involve a range of behaviors at different ages and degrees of functioning, thus the term “autism spectrum disorder”. Along with these changes in classification, there has been a greater understanding of the causes of autism. Developmental delay, epilepsy, minor facial and bodily abnormalities, increased rate of obstetrical complications, an unequal sex ratio, and extremes of head size represent subtle, but still not clearly defined, signs that autism is a neuropsychiatric disorder. It appears that pharmacological interventions may have a limited role to play in the overall therapy of the autistic child. Medications may be most helpful in reducing hyperactivity, impulsivity, and aggressive and obsessive behaviors. For the development of everyday life skills, one-on-one behavioral therapy seems to be mandatory.
Export Options
About this article
Cite this article as:
Mohammadi Mohammad-Reza and Akhondzadeh Shahin, Autism Spectrum Disorders: Etiology and Pharmacotherapy, Current Drug Therapy 2007; 2 (2) . https://dx.doi.org/10.2174/157488507780619095
DOI https://dx.doi.org/10.2174/157488507780619095 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medial Temporal Lobe Volumes in Amnestic Mild Cognitive Impairment and Late-life Depression: Research Synthesis
Current Psychiatry Reviews The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Glutamate as a Modulator of Embryonic and Adult Neurogenesis
Current Topics in Medicinal Chemistry A Longitudinal Study of Alterations of S100B, sRAGE and Fas Ligand in Association to Olanzapine Medication in a Sample of First Episode Patients with Schizophrenia
CNS & Neurological Disorders - Drug Targets Lipophilicity and Other Parameters Affecting Brain Penetration
Current Medicinal Chemistry - Central Nervous System Agents <i>Thespesia populnea</i>: An Ethnomedicinal, Phytochemical and Pharmacological Review
The Natural Products Journal Benzodiazepines and Sleep Architecture: A Systematic Review
CNS & Neurological Disorders - Drug Targets An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry The Interaction of DNA-Binding Ligands with Trinucleotide-Repeat DNA: Implications for Therapy and Diagnosis of Neurological Disorders
Current Topics in Medicinal Chemistry Plant Derived Inhibitor Sulforaphane in Combinatorial Therapy Against Therapeutically Challenging Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry Experimental Drugs for Neuropathic Pain
Current Neuropharmacology Valproate Induced Acute Pancreatitis - A Unique Case Report
Current Drug Safety subject Index To Volume 1
Current Drug Targets - CNS & Neurological Disorders Editorial [Hot Topic: PET and SPECT in Drug Evaluation and Drug Design Imaging Inflammatory Processes, Tumors, and the Endocannabinoid System(Executive Editor: Aren van Waarde)]
Current Pharmaceutical Design Novel 3-{4-[2-Amino-4-(Substitutedphenyl)-2H-[1, 3] Oxazin/Thiazin-6-Yl} -2-Phenyl-3H-Quinazolin-4-One Derivatives as Enhancer of GABA Mediated Inhibition: Synthesis, Molecular Modeling and Pharmacological Studies
Letters in Drug Design & Discovery Quantification of Iron Deposition in the Brain of Hypertensive Patients using 3D-enhanced Susceptibility-weighted Angiography (ESWAN)
Current Medical Imaging Thiosemicarbazone-benzenesulfonamide Derivatives as Human Carbonic Anhydrases Inhibitors: Synthesis, Characterization, and <i>In silico</i> Studies
Anti-Cancer Agents in Medicinal Chemistry Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Current Topics in Medicinal Chemistry Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy